References of "Sorensen, O"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailVertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors
Roux, Christian; Reginster, Jean-Yves ULg; Fechtenbaum, Jacques et al

in Osteoporosis International (2006, June), 17(Suppl.2), 92

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fracture status
Fardellone, P.; Roux, C.; Fechtenbaum, J. et al

in BONE (2005), 36(S2), 403

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 584-5

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of 5-year risedronate therapy on fracture reduction and bone histology and histomorphometry
Watts, NB; Sorensen, O; Eriksen, E et al

in Arthritis and Rheumatism (2001), 44(1220), 256

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailRisedronate reduces fracture risk in women with established postmenopausal osteoporosis
Eastell, R; Minne, H; Sorensen, O et al

in Calcified Tissue International (1999), 64(S1), 43

Detailed reference viewed: 6 (2 ULg)